Donald R. VanDevanter
YOU?
Author Swipe
View article: Differences in pulmonary exacerbation risks among CF subpopulations
Differences in pulmonary exacerbation risks among CF subpopulations Open
Prior-year PEx frequency (treated by any route) was strongly associated with future PEx risk independent of modulator use. Although ETI reduces PEx rates, agents intended to further reduce rates can be studied in pwCF receiving ETI having …
View article: ECFS standards of care on CFTR-related disorders: Identification and care of the disorders
ECFS standards of care on CFTR-related disorders: Identification and care of the disorders Open
View article: Creation of a CF-specific antibiotic spectrum index (ASI) as an antimicrobial stewardship initiative
Creation of a CF-specific antibiotic spectrum index (ASI) as an antimicrobial stewardship initiative Open
Antibiotics are frequently utilized for cystic fibrosis (CF)-related pulmonary exacerbation treatment. The antibiotic spectrum index (ASI) is an antimicrobial stewardship tool developed to compare the relative breadth of individual antibio…
View article: Heterogeneity of CFTR modulator-induced sweat chloride concentrations in people with cystic fibrosis
Heterogeneity of CFTR modulator-induced sweat chloride concentrations in people with cystic fibrosis Open
View article: Adjunctive Systemic Corticosteroids for Pulmonary Exacerbations of Cystic Fibrosis
Adjunctive Systemic Corticosteroids for Pulmonary Exacerbations of Cystic Fibrosis Open
Rationale: Pulmonary exacerbations (PEx) remain the most common cause of morbidity, recurrent hospitalization, and diminished survival in people with cystic fibrosis (PWCF) and are characterized by excess inflammation. Corticosteroi…
View article: Longitudinal bacterial prevalence in cystic fibrosis airways: Fact and artifact
Longitudinal bacterial prevalence in cystic fibrosis airways: Fact and artifact Open
View article: 697 Rationale and development of a cystic fibrosis–specific antibiotic spectrum index as a stewardship initiative
697 Rationale and development of a cystic fibrosis–specific antibiotic spectrum index as a stewardship initiative Open
View article: Impact of lumacaftor/ivacaftor and tezacaftor/ivacaftor on treatment response in pulmonary exacerbations of F508del/F508del cystic fibrosis
Impact of lumacaftor/ivacaftor and tezacaftor/ivacaftor on treatment response in pulmonary exacerbations of F508del/F508del cystic fibrosis Open
View article: WS03.05 Multicenter validation of the cystic fibrosis-ABLE score as a predictor of outcome and therapeutic response in cystic fibrosis
WS03.05 Multicenter validation of the cystic fibrosis-ABLE score as a predictor of outcome and therapeutic response in cystic fibrosis Open
View article: Willingness of people with cystic fibrosis receiving elexacaftor/tezacaftor/ivacaftor (ETI) to participate in randomized modulator and inhaled antimicrobial clinical trials
Willingness of people with cystic fibrosis receiving elexacaftor/tezacaftor/ivacaftor (ETI) to participate in randomized modulator and inhaled antimicrobial clinical trials Open
View article: Re-examining baseline lung function recovery following IV-treated pulmonary exacerbations
Re-examining baseline lung function recovery following IV-treated pulmonary exacerbations Open
View article: Standards of care for CFTR variant-specific therapy (including modulators) for people with cystic fibrosis
Standards of care for CFTR variant-specific therapy (including modulators) for people with cystic fibrosis Open
View article: Characterizing CFTR modulated sweat chloride response across the cf population: Initial results from the CHEC-SC study
Characterizing CFTR modulated sweat chloride response across the cf population: Initial results from the CHEC-SC study Open
View article: Changes in airway bacterial communities occur soon after initiation of antibiotic treatment of pulmonary exacerbations in cystic fibrosis
Changes in airway bacterial communities occur soon after initiation of antibiotic treatment of pulmonary exacerbations in cystic fibrosis Open
View article: Antipseudomonal treatment decisions during CF exacerbation management
Antipseudomonal treatment decisions during CF exacerbation management Open
View article: Health care costs in a randomized trial of antimicrobial duration among cystic fibrosis patients with pulmonary exacerbations
Health care costs in a randomized trial of antimicrobial duration among cystic fibrosis patients with pulmonary exacerbations Open
View article: What shall we learn from TEACH?
What shall we learn from TEACH? Open
View article: Association of site of treatment with clinical outcomes following intravenous antimicrobial treatment of a pulmonary exacerbation
Association of site of treatment with clinical outcomes following intravenous antimicrobial treatment of a pulmonary exacerbation Open
View article: 153: Site of intravenous antimicrobial treatment of pulmonary exacerbations in the STOP2 study: Home versus hospital
153: Site of intravenous antimicrobial treatment of pulmonary exacerbations in the STOP2 study: Home versus hospital Open
View article: 555: Clinical trial interest after establishment of modulator therapy: Interim CHEC-SC survey results
555: Clinical trial interest after establishment of modulator therapy: Interim CHEC-SC survey results Open
View article: 157: C-reactive protein (CRP) as a biomarker of exacerbation presentation and treatment response
157: C-reactive protein (CRP) as a biomarker of exacerbation presentation and treatment response Open
View article: Measuring the impact of CFTR modulation on sweat chloride in cystic fibrosis: Rationale and design of the CHEC-SC study
Measuring the impact of CFTR modulation on sweat chloride in cystic fibrosis: Rationale and design of the CHEC-SC study Open
View article: Epidemiologic Study of Cystic Fibrosis: 25 years of observational research
Epidemiologic Study of Cystic Fibrosis: 25 years of observational research Open
The Epidemiologic Study of Cystic Fibrosis (ESCF) was a prospective observational study of over 32,000 people with cystic fibrosis (CF) from 250 clinical care sites in North America from 1994 to 2005. Begun as a pharmacovigilance study in …
View article: Accelerated Approval or Risk Reduction? How Response Biomarkers Advance Therapeutics through Clinical Trials in Cystic Fibrosis
Accelerated Approval or Risk Reduction? How Response Biomarkers Advance Therapeutics through Clinical Trials in Cystic Fibrosis Open
View article: Changes in symptom scores as a potential clinical endpoint for studies of cystic fibrosis pulmonary exacerbation treatment
Changes in symptom scores as a potential clinical endpoint for studies of cystic fibrosis pulmonary exacerbation treatment Open
View article: Association of Inhaled Antibiotics in Addition to Standard Intravenous Therapy and Outcomes of Pediatric Inpatient Pulmonary Exacerbations
Association of Inhaled Antibiotics in Addition to Standard Intravenous Therapy and Outcomes of Pediatric Inpatient Pulmonary Exacerbations Open
Rationale: Considerable morbidity and disease progression in people with cystic fibrosis (CF) result from pulmonary exacerbations (PExs). PEx guidelines note insufficient evidence to recommend for or against the concomitant use of i…
View article: Evaluating assumptions of definition-based pulmonary exacerbation endpoints in cystic fibrosis clinical trials
Evaluating assumptions of definition-based pulmonary exacerbation endpoints in cystic fibrosis clinical trials Open
View article: Antimicrobial resistance: Concerns of healthcare providers and people with CF
Antimicrobial resistance: Concerns of healthcare providers and people with CF Open
View article: Building global development strategies for cf therapeutics during a transitional cftr modulator era
Building global development strategies for cf therapeutics during a transitional cftr modulator era Open
View article: Pseudomonas aeruginosa antimicrobial susceptibility test (AST) results and pulmonary exacerbation treatment responses in cystic fibrosis
Pseudomonas aeruginosa antimicrobial susceptibility test (AST) results and pulmonary exacerbation treatment responses in cystic fibrosis Open